Literature DB >> 10831516

Edge restenosis after implantation of high activity (32)P radioactive beta-emitting stents.

R Albiero1, T Nishida, M Adamian, A Amato, M Vaghetti, N Corvaja, C Di Mario, A Colombo.   

Abstract

BACKGROUND: A high restenosis rate has been reported at the edges ("edge restenosis") of (32)P radioactive stents with an initial activity level of 3 to 12 microCi. This edge effect might be due to balloon injury and to a low dose of radiation at the stent margins. The aim of this study was to evaluate whether the implantation of (32)P radioactive stents with a higher activity level (12 to 21 microCi) combined with a nonaggressive stent implantation strategy could solve the problem of edge restenosis. METHODS AND
RESULTS: We compared the results of lesions treated with single radioactive BX stents with an activity of 12 to 21 microCi (group 2, n = 54 lesions) with the results of lesions treated by single radioactive BX stents with an initial activity level of 3 to 12 microCi (group 1, n = 42 lesions). There were no procedural events. At the 6-month follow-up, no myocardial infarctions, deaths, or stent thromboses had occurred. Intrastent binary restenosis was 0% in group 1 versus 4% in group 2 (n = 2, both at the ostium of the right coronary artery, P = NS). Intrastent neointimal hyperplasia was significantly lower in group 2 than in group 1. The intralesion (intrastent plus peri-stent) restenosis rate was 38% in group 1 versus 30% in group 2 (P = NS). Conclusions-Single (32)P radioactive stents with an initial activity level of 12 to 21 microCi reduced intrastent neointimal hyperplasia compared with stents of 3 to 12 microCi, but they did not solve the problem of edge restenosis, even if a nonaggressive stent implantation strategy was used.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10831516     DOI: 10.1161/01.cir.101.21.2454

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  8 in total

1.  Comparative study of tacrolimus and paclitaxel stent coating in the porcine coronary model.

Authors:  B Scheller; A Grandt; S Wnendt; G Lorenz; M Böhm; G Nickenig
Journal:  Z Kardiol       Date:  2005-07

2.  Restenosis after Angioplasty.

Authors:  Mehran Moussavian; Peter J. Casterella; Paul S. Teirstein
Journal:  Curr Treat Options Cardiovasc Med       Date:  2001-04

3.  Endovascular gamma irradiation for the prevention restenosis after angioplasty of femoropopliteal de novo stenoses.

Authors:  Karsten Krueger; Mark Bendel; Markus Zaehringer; David Strohe; Christopher Bangard; Carsten Weise; Rolf-Peter Mueller; Klaus Lackner
Journal:  Eur Radiol       Date:  2005-08-23       Impact factor: 5.315

Review 4.  Cardiovascular gene delivery: The good road is awaiting.

Authors:  L P Brewster; E M Brey; H P Greisler
Journal:  Adv Drug Deliv Rev       Date:  2006-07-07       Impact factor: 15.470

Review 5.  Prevention of restenosis with intravascular beta-radiotherapy.

Authors:  G L Kaluza; P T Zymek; A E Raizner
Journal:  Curr Atheroscler Rep       Date:  2001-03       Impact factor: 5.113

Review 6.  Intravascular brachytherapy for peripheral vascular disease.

Authors:  Alina Andras; Monica Hansrani; Marlene Stewart; Gerard Stansby
Journal:  Cochrane Database Syst Rev       Date:  2014-01-08

7.  Development and pre-clinical test of a phosphorous-32 containing polyetheretherketone foil aiming at urethral stricture prevention by low-dose-rate brachytherapy.

Authors:  Walter Assmann; Ricarda Becker; Christian Stief; Ronald Sroka
Journal:  J Contemp Brachytherapy       Date:  2022-04-02

Review 8.  Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V).

Authors:  Imad Sheiban; Gianluca Villata; Mario Bollati; Dario Sillano; Marzia Lotrionte; Giuseppe Biondi-Zoccai
Journal:  Vasc Health Risk Manag       Date:  2008
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.